Brief: Maia Biotechnology Announces FDA Clearance Of Ind Application For Thio, A Telomere Targeting Agent For The Treatment Of Non-Small Cell Lung Cancer
03/10/2023 13:52
Oct 3 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE
TREATMENT OF NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBw5RrMvFa
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale